CRISIL Ltd. Upgraded to Buy by MarketsMOJO on Strong Technical and Financial Grounds

Quality Assessment: Robust Fundamentals Amidst Growth Challenges

CRISIL’s quality metrics remain strong, underpinned by high management efficiency and a net-debt-free balance sheet. The company reported a return on equity (ROE) of 27.03% in the latest financials, with a return on capital employed (ROCE) of 40.16%, signalling effective capital utilisation. The recent quarterly results for Q1 FY26-27 further reinforce this strength, with net sales rising 27.56% year-on-year to ₹1,075.39 crores, profit before tax excluding other income growing 28.43% to ₹258.70 crores, and net profit increasing 26.2% to ₹216.46 crores.

However, despite these positive indicators, the company’s long-term sales growth rate remains moderate at an annualised 14.40% over the past five years. This suggests some caution regarding sustained expansion, which tempers the overall quality outlook. The majority shareholding by promoters adds stability but also concentrates control.

Valuation: Elevated but Justified by Performance

The valuation grade for CRISIL has been downgraded from expensive to very expensive, reflecting a premium pricing relative to its peers and historical averages. The company trades at a price-to-earnings (PE) ratio of 38.29, significantly higher than CARE Ratings’ 27.75 and ICRA’s 22.22. Its enterprise value to EBITDA (EV/EBITDA) ratio stands at 27.07, again above industry comparators.

Price to book value is at 10.35, indicating a substantial premium on net assets, while the PEG ratio of 1.78 suggests that earnings growth is priced in but not excessively stretched. Dividend yield remains modest at 1.36%, consistent with a growth-oriented profile. Investors should note that while the valuation is high, it aligns with CRISIL’s superior profitability metrics and market positioning within the ratings industry.

Financial Trend: Positive Momentum with Mixed Long-Term Signals

CRISIL’s financial trend has shown encouraging signs in the recent quarter, with double-digit growth in sales and profits. Year-to-date (YTD) stock returns of 6.45% outperform the Sensex’s negative 12.19%, indicating relative strength in market performance. Over the past five years, the stock has delivered a 59.59% return, more than double the Sensex’s 24.95% in the same period.

However, the one-year return of -5.11% lags the broader market’s -8.86%, reflecting some short-term volatility. Profit growth over the past year has been robust at 21.5%, supporting the company’s earnings quality despite the stock price dip. The PEG ratio near 1.8 suggests that earnings growth is reasonably priced, but investors should remain vigilant about the sustainability of this trend given the moderate long-term sales growth.

Technical Analysis: Upgrade to Bullish Momentum

The technical grade for CRISIL has been upgraded from mildly bullish to bullish, driven by a confluence of positive indicators across multiple timeframes. On the weekly chart, the MACD is bullish, supported by a bullish KST and mildly bullish Bollinger Bands. The daily moving averages also confirm a bullish trend, reinforcing short-term momentum.

Monthly indicators present a more mixed picture, with MACD and KST showing bearish signals, though Bollinger Bands remain mildly bullish and on-balance volume (OBV) is bullish. The Dow Theory signals no clear weekly trend but mildly bullish monthly trends, suggesting some caution for longer-term technical outlooks.

Price action has been steady, with the stock closing at ₹4,604.05 on 23 September 2026, up 0.84% on the day, trading near its 52-week high of ₹5,060.00. The recent trading range between ₹4,512.05 and ₹4,630.00 indicates consolidation with upward bias, supporting the bullish technical upgrade.

Comparative Performance and Industry Context

Within the ratings industry, CRISIL’s valuation metrics stand out as the most expensive compared to peers such as CARE Ratings and ICRA. CARE Ratings trades at a PE of 27.75 and EV/EBITDA of 23.54, while ICRA is valued at a PE of 22.22 and EV/EBITDA of 15.73. CRISIL’s premium valuation is supported by its superior profitability and consistent financial performance, but investors should weigh this against the risk of valuation compression if growth slows.

Over the long term, CRISIL has outperformed the Sensex in three- and five-year horizons, with returns of 19.48% and 59.59% respectively, compared to the Sensex’s 13.36% and 24.95%. However, its ten-year return of 108.84% trails the Sensex’s 161.01%, indicating some relative underperformance over the very long term.

Risks and Considerations

Despite the upgrade, investors should remain mindful of certain risks. The company’s long-term sales growth rate of 14.40% is moderate, which may limit upside potential. The very expensive valuation metrics imply limited margin for error, especially if earnings growth decelerates. Additionally, the mixed monthly technical signals suggest that momentum could face resistance in the medium term.

Furthermore, while CRISIL is net-debt free and enjoys strong management efficiency, the concentrated promoter ownership may pose governance considerations for some investors. The modest dividend yield of 1.36% also indicates that returns are primarily driven by capital appreciation rather than income.

Conclusion: A Buy with Cautious Optimism

The upgrade of CRISIL Ltd. from Hold to Buy reflects a balanced assessment of its strong quality fundamentals, positive financial trends, and improving technical momentum, despite a very expensive valuation. The company’s robust profitability, net-debt-free status, and recent quarterly growth underpin confidence in its near-term prospects. However, investors should remain vigilant about valuation risks and moderate long-term growth rates.

Overall, CRISIL presents a compelling opportunity for investors seeking exposure to the capital markets sector with a well-managed, financially sound company exhibiting bullish technical signals. The upgrade signals increased conviction in the stock’s ability to deliver value, making it a noteworthy addition to portfolios focused on quality and momentum.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →